NYSE : FC

Franklin Covey Co.

$20.28 USD

-$0.22 (-1.07%)

Volume
81.61K
Average Volume
96.09K
Market Capitalization
$229.04M
P/E Ratio
112.67
Dividend Yield
0.00%
Price Target
$25.00
Year High
$26.81
Year Low
$11.16
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$0.66
Source Headline
FC Investors Have Opportunity to Join Franklin Covey Co. Fraud Investigation with the Schall Law Firm

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Franklin C

gurufocus.com - 2026-07-18 23:00:00

FC Investors Have Opportunity to Join Franklin Covey Co. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)---- $FC--FC Investors Have Opportunity to Join Franklin Covey Co. Fraud Investigation with the Schall Law Firm.

businesswire.com - 2026-07-18 22:31:00

Franklin Covey Showcases ‘Presenting for Impact' to Turn Messages Into Action

Franklin Covey NYSE: FC used a recent webinar to showcase its “Presenting for Impact” content, positioning the offering as a practical framework for helping leaders communicate with more clarity, audience connection and action-oriented intent.

marketbeat.com - 2026-07-17 13:03:38

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Franklin Covey Co. - FC

NEW YORK, July 16, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Franklin Covey Co. ("Franklin Covey" or the "Company") (NYSE: FC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-07-16 10:00:00

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Franklin Covey Co. - FC

NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Franklin Covey Co. (“Franklin Covey” or the “Company”) (NYSE: FC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

globenewswire.com - 2026-07-14 16:49:00

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Franklin Covey Co. - FC

NEW YORK, July 9, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Franklin Covey Co. ("Franklin Covey" or the "Company") (NYSE: FC).  Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

prnewswire.com - 2026-07-09 19:57:00

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Franklin Covey Co. - FC

NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Franklin Covey Co. (“Franklin Covey” or the “Company”) (NYSE: FC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

globenewswire.com - 2026-07-07 17:21:00

Why Franklin Covey Stock Plummeted Today

Franklin Covey posted its quarterly results yesterday, and results were worse than expected. The company also lowered its full-year performance outlookk.

fool.com - 2026-07-02 16:32:32

FC Q3 Earnings Call Points to Stronger 2027 Setup

Franklin Covey says deferred revenues, booked services and North America execution are setting up a stronger fiscal 2027 despite a lower 2026 revenue view.

zacks.com - 2026-07-02 08:31:10

Franklin Covey Cuts Revenue Forecast, Joins Ouster And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.2% on Thursday.

benzinga.com - 2026-07-02 08:02:04

Lindsay, Franklin Covey And 3 Stocks To Watch Heading Into Thursday

With U.S. stock futures trading slightly lower this morning on Thursday, some of the stocks that may grab investor focus today are as follows:

benzinga.com - 2026-07-02 03:43:17

Franklin Covey Co. (FC) Q3 2026 Earnings Call Transcript

Franklin Covey Co. (FC) Q3 2026 Earnings Call Transcript

seekingalpha.com - 2026-07-01 23:26:48

Franklin Covey Reports Third Quarter Fiscal 2026 Financial Results

SALT LAKE CITY--(BUSINESS WIRE)--Franklin Covey Co. (NYSE: FC), a global leadership and organizational performance partner that gives strategy the human edge, announced today its financial results for the third quarter of fiscal 2026, which ended on May 31, 2026. Third Quarter Fiscal 2026 Financial Overview The Company's consolidated revenue for Q3 FY2026 increased to $67.8 million compared with $67.1 million in Q3 FY2025. The Company's financial results for Q3 FY2026 include the following: Ent.

businesswire.com - 2026-07-01 16:15:00

The AI Winners Won't Just Be The Most Technological. They'll Be The Most Human.

SALT LAKE CITY--(BUSINESS WIRE)-- #AI--The AI Winners Won't Just Be The Most Technological. They'll Be The Most Human.

businesswire.com - 2026-07-01 09:08:00

Franklin Covey Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Franklin Covey Co. (NYSE:FC) will release its third quarter earnings report after the closing bell on Wednesday, July 1.

benzinga.com - 2026-06-25 02:35:53

Franklin Covey to Report Third Quarter Fiscal 2026 Results

SALT LAKE CITY--(BUSINESS WIRE)--Franklin Covey Co. (NYSE: FC), a global leadership and organizational performance partner that gives strategy the human edge, announced today that the conference call to review the Company's third quarter 2026 financial results will take place on Wednesday, July 1, 2026, at 5:00 p.m. ET (3:00 p.m. MT). The Company's financial results are expected to be released after the close of the market on Wednesday, July 1, 2026. Interested persons may access a live webcast.

businesswire.com - 2026-06-17 16:30:00

Firm Capital Mortgage Investment Corporation Announces Election of Directors

/NOT FOR DISTRIBUTION OVER U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES/ TORONTO, June 16, 2026 (GLOBE NEWSWIRE) -- Firm Capital Mortgage Investment Corporation (the “Corporation”) (TSX: FC) today announced that at the annual and special meeting (the “Meeting”) of shareholders of the Corporation held earlier today, all director nominees were elected as directors of the Corporation, as follows: Nominee Votes “For” % Votes “For” Votes“Against” % of Votes“Against” Geoffrey Bledin 6,765,492 98.74% 86,421 1.26% Eli Dadouch 6,766,598 98.75% 85,315 1.25% Morris Fischtein 6,695,934 97.72% 155,979 2.28% Stanley Goldfarb 6,506,702 94.96% 345,211 5.04% Victoria Granovski 6,727,004 98.18% 124,909 1.82% Anthony Heller 6,670,338 97.35% 181,575 2.65% Jonathan Mair 6,726,174 98.16% 125,739 1.84% Francis Newbould 6,767,416 98.77% 84,497 1.23% Joe Oliver 6,745,850 98.45% 106,063 1.55% Keith Ray 6,764,118 98.72% 87,795 1.28% Lawrence Shulman 6,733,213 98.27% 118,700 1.73% Michael Warner 6,733,298 98.27% 118,615 1.73% *  The number of votes disclosed reflects proxies received by management of the Corporation in advance of the Meeting. All other matters considered by shareholders at the Meeting were also approved, the details of which are contained in the Report on Voting Results regarding the Meeting filed by the Corporation on SEDAR+ at www.sedarplus.ca.

globenewswire.com - 2026-06-16 17:01:00

FranklinCovey Will Host James Patterson, Liz Wiseman, Patrick Leddin and Jennifer Colosimo to Help HR and L&D Leaders Close Critical Leadership Gaps and Lead Through Disruption

[url="]FranklinCovey[/url] ([url="]NYSE: FC[/url]), a global leader in organizational performance improvement, today announced it will host James Patterson, Liz

gurufocus.com - 2026-06-15 10:00:00

FranklinCovey Will Host James Patterson, Liz Wiseman, Patrick Leddin and Jennifer Colosimo to Help HR and L&D Leaders Close Critical Leadership Gaps and Lead Through Disruption

SALT LAKE CITY--(BUSINESS WIRE)-- #Change--FranklinCovey will Host James Patterson, Liz Wiseman, Patrick Leddin and Jennifer Colosimo on Two Webinars for HR and L&D Leaders on June 26 and 30.

businesswire.com - 2026-06-15 09:12:00

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living wi

gurufocus.com - 2026-05-27 10:01:00

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC. With thi.

businesswire.com - 2026-05-27 10:00:00

80% of Individual Contributors Say Their Manager's Approach to AI is Hands-Off, FranklinCovey Research Finds

As organizations race to capture the benefits of artificial intelligence, research from [url="]FranklinCovey[/url] Institute reveals a critical obstacle: most

gurufocus.com - 2026-05-21 13:00:00

80% of Individual Contributors Say Their Manager's Approach to AI is Hands-Off, FranklinCovey Research Finds

SALT LAKE CITY--(BUSINESS WIRE)-- #AI--As organizations race to capture the benefits of artificial intelligence, research from FranklinCovey Institute reveals a critical obstacle: most employees feel they are navigating AI alone, without meaningful support or guidance. Eighty percent of individual contributors describe their manager's approach to AI as “hands-off,” which underscores a widening gap between AI's potential and how it's actually used at work. FranklinCovey's 2025 AI General Attitudes Sur.

businesswire.com - 2026-05-21 12:38:00

Diploma H1 Earnings Call Highlights

Diploma LON: DPLM reported what management described as a “very strong” first half for the six months ended March 31, 2026, with double-digit organic growth, higher margins and upgraded full-year expectations.

marketbeat.com - 2026-05-19 05:07:03

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that full results of its ADVANCE OUTCOMES study are being present

gurufocus.com - 2026-05-17 15:00:00

Firm Capital Mortgage Investment Corporation Announces Q1/2026 Results and Declares Monthly Cash Dividends for July, August and September 2026

TORONTO, May 05, 2026 (GLOBE NEWSWIRE) -- Firm Capital Mortgage Investment Corporation (the “Corporation”) (TSX FC, FC.DB. K, FC.DB. L and FC.DB.M) today released its financial statements for the three months ended March 31, 2026.

globenewswire.com - 2026-05-05 17:01:00

Get FC Insider Trade Alerts

FC Price Target Summary

Last Month

$25.00

1 analysts

Last Quarter

$25.00

1 analysts

Last Year

$24.00

3 analysts

All Time

$45.40

5 analysts

FC Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-07-02 Roth Capital Maintain Buy Buy
2026-07-02 Barrington Research Maintain Outperform Outperform
2026-06-05 Barrington Research Maintain Outperform Outperform
2026-04-02 Barrington Research Maintain Outperform Outperform
2026-03-25 Barrington Research Maintain Outperform Outperform
2026-01-20 Barrington Research Maintain Outperform Outperform
2026-01-08 Barrington Research Maintain Outperform Outperform
2025-12-11 Barrington Research Maintain Outperform Outperform
2025-11-06 Barrington Research Maintain Outperform Outperform
2025-08-19 Barrington Research Maintain Outperform Outperform
2025-07-07 Roth Capital Maintain Buy Buy
2025-07-03 Barrington Research Maintain Outperform Outperform
2025-04-10 Barrington Research Maintain Outperform Outperform
2025-04-03 Barrington Research Maintain Outperform Outperform
2025-03-21 Barrington Research Maintain Outperform Outperform
2024-11-07 Barrington Research Maintain Outperform Outperform
2024-10-28 Barrington Research Maintain Outperform Outperform
2024-06-27 Roth MKM Maintain Buy Buy
2024-06-27 Barrington Research Maintain Outperform Outperform
2024-06-18 Barrington Research Maintain Outperform Outperform
2024-05-28 Barrington Research Maintain Outperform Outperform
2024-04-08 Barrington Research Maintain Outperform Outperform
2024-03-28 Barrington Research Maintain Outperform Outperform
2024-03-28 Northland Capital Markets Maintain Outperform Outperform
2024-03-22 Barrington Research Maintain Outperform Outperform
2024-01-03 Barrington Research Maintain Outperform Outperform
2023-12-19 Roth MKM Maintain Buy Buy
2023-06-29 Northland Capital Markets Maintain Outperform Outperform
2023-06-29 Barrington Research Maintain Outperform Outperform
2023-06-29 Roth MKM Maintain Buy Buy
2023-06-20 Barrington Research Maintain Outperform Outperform
2023-05-25 Barrington Research Maintain Outperform Outperform
2023-03-30 Northland Capital Markets Maintain Outperform Outperform
2023-03-30 Barrington Research Maintain Outperform Outperform
2023-03-30 Roth MKM Maintain Buy Buy
2022-11-17 Northland Capital Markets Maintain Outperform Outperform
2021-07-02 Roth Capital Maintain Buy Buy
2021-04-05 Roth Capital Maintain Buy Buy
2020-04-03 B. Riley FBR Maintain Buy Buy
2020-04-03 B. Riley Securities Maintain Buy Buy
2020-03-30 B. Riley Securities Maintain Buy Buy
2020-03-30 B. Riley FBR Maintain Buy Buy
2018-09-17 B. Riley FBR Maintain Buy Buy
2018-09-17 B. Riley Securities Maintain Buy Buy
2018-05-05 B. Riley FBR Maintain Buy Buy
2017-11-10 B. Riley Maintain Buy Buy
2017-11-10 B. Riley FBR Maintain Buy Buy
2017-11-10 B. Riley Securities Maintain Buy Buy
2016-12-28 Barrington Research Downgrade Outperform Market Perform
2015-11-05 B. Riley Maintain Buy Buy
2015-11-05 William Blair Downgrade Outperform Market Perform
2015-11-05 B. Riley Securities Maintain Buy Buy
2015-11-05 B. Riley FBR Maintain Buy Buy
2015-07-02 B. Riley Maintain Buy Buy
2015-07-02 B. Riley Securities Maintain Buy Buy
2015-07-02 B. Riley FBR Maintain Buy Buy
2014-03-21 William Blair Maintain Outperform Outperform
2013-09-17 B. Riley Maintain Buy Buy
2013-09-17 B. Riley FBR Maintain Buy Buy
2012-11-01 Roth Capital Maintain Buy Buy